欧盟/欧洲经济区及全球人乳头瘤病毒疫苗接种:一个道德困境
本文综述了欧盟/欧洲经济区国家将人乳头瘤病毒(HPV)疫苗接种扩展至男孩的政策,以及世界卫生组织免疫战略咨询专家组的建议,讨论全球疫苗供应短缺背景下的挑战与剂量节约方案。部分欧盟/欧洲经济区国家已将HPV疫苗接种扩展至男孩,欧洲癌症组织发布了消除两性所有HPV相关癌症的决议,但疫苗供应短缺预计至少持续至2024年。
要点
- 全球约50%的国家已引入HPV疫苗接种。
- WHO于2018年发出消除宫颈癌的呼吁,但全球HPV疫苗短缺预计至少持续至2024年。
- 欧洲疾病预防控制中心2020年指南认为,将常规接种扩展至男孩的成本效果取决于多个情境特异性因素。
核心结论
- 欧盟/欧洲经济区国家将HPV疫苗接种扩展至男孩可能影响全球疫苗的可及性。
- 在COVID-19大流行后时期,可考虑临时剂量节约方案。
研究设计与样本
- 综述了欧盟/欧洲经济区国家的国家政策以及世界卫生组织免疫战略咨询专家组的建议。
主要发现
- 全球约50%的国家已引入HPV疫苗接种。
- 一些宫颈癌负担高的低收入和中等收入国家尚未引入HPV疫苗接种,或接种覆盖率未达最佳水平。
- 全球HPV疫苗短缺预计至少持续至2024年。
- 若干欧盟/欧洲经济区国家已将HPV疫苗接种扩展至男孩。
- 欧洲癌症组织已发布决议,旨在消除两性所有HPV相关癌症。
关键数值与推荐
- 欧洲疾病预防控制中心2020年指南得出结论:将常规接种扩展至男孩的成本效果取决于多个情境特异性因素。
临床怎么用
- 在COVID-19大流行后时期,可考虑临时剂量节约方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While many European Union/European Economic Area (EU/EEA) countries recently expanded human papillomavirus (HPV) vaccination to boys, HPV vaccine supply is currently limited for girls in low- and middle-income countries (LMIC) that are severely affected by HPV.Globally, about 50% of countries have introduced HPV vaccination. Some LMIC with high burden of cervical cancer have not yet introduced HPV vaccination, or are reaching suboptimal vaccination coverage. While WHO issued a call for cervical cancer elimination in 2018, a global shortage of HPV vaccines is currently predicted to last at least until 2024.We reviewed national policies of EU/EEA countries and recommendations of the World Health Organization (WHO) Strategic Advisory Group of Experts on immunisation to discuss current challenges and dose-sparing options. Several EU/EEA countries have extended HPV vaccination to boys and the European Cancer Organisation has issued a resolution for elimination of all HPV-associated cancers in both sexes. The European Centre for Disease Prevention and Control concluded in its 2020 guidance that cost-effectiveness of extending routine vaccination to boys depends on several context-specific factors. The extension of HPV vaccination to boys in EU/EEA countries may affect global availability of vaccines. Temporary dose-sparing options could be considered during the COVID-19 post-pandemic period.
引用
- Colzani E, Johansen K, Johnson H, et al. Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma. Euro Surveill. 2021. PMID: 34915976. doi:10.2807/1560-7917.ES.2021.26.50.2001659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。